- Conditions
- Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
- Interventions
- Dapagliflozin, Saxagliptin, Pioglitazone, Metformin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hyperglycemia, Diabetes Mellitus
- Interventions
- Lantus® (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
- Interventions
- Not listed
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12,537 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Prediabetic State
- Interventions
- Rimonabant, Placebo (for Rimonabant)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 2,420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Obesity
- Interventions
- Sitagliptin Phosphate
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Aurora, Colorado